JP2016011272A5 - - Google Patents

Download PDF

Info

Publication number
JP2016011272A5
JP2016011272A5 JP2014133377A JP2014133377A JP2016011272A5 JP 2016011272 A5 JP2016011272 A5 JP 2016011272A5 JP 2014133377 A JP2014133377 A JP 2014133377A JP 2014133377 A JP2014133377 A JP 2014133377A JP 2016011272 A5 JP2016011272 A5 JP 2016011272A5
Authority
JP
Japan
Prior art keywords
microrna
control agent
immune response
response control
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014133377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016011272A (ja
JP6385732B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2014133377A priority Critical patent/JP6385732B2/ja
Priority claimed from JP2014133377A external-priority patent/JP6385732B2/ja
Publication of JP2016011272A publication Critical patent/JP2016011272A/ja
Publication of JP2016011272A5 publication Critical patent/JP2016011272A5/ja
Application granted granted Critical
Publication of JP6385732B2 publication Critical patent/JP6385732B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014133377A 2014-06-27 2014-06-27 免疫応答制御剤 Active JP6385732B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014133377A JP6385732B2 (ja) 2014-06-27 2014-06-27 免疫応答制御剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014133377A JP6385732B2 (ja) 2014-06-27 2014-06-27 免疫応答制御剤

Publications (3)

Publication Number Publication Date
JP2016011272A JP2016011272A (ja) 2016-01-21
JP2016011272A5 true JP2016011272A5 (enExample) 2018-03-01
JP6385732B2 JP6385732B2 (ja) 2018-09-05

Family

ID=55228217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014133377A Active JP6385732B2 (ja) 2014-06-27 2014-06-27 免疫応答制御剤

Country Status (1)

Country Link
JP (1) JP6385732B2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6566612B2 (ja) * 2014-06-27 2019-08-28 国立大学法人北海道大学 免疫体質又は免疫応答型を判定するためのバイオマーカー及び免疫応答型制御剤
CN108853132A (zh) * 2018-05-22 2018-11-23 深圳先进技术研究院 一种miR-340调控IL-17A表达的用途
US20220177967A1 (en) * 2019-03-08 2022-06-09 Edward E. Winger, M.D., Professional Corporation Reagents, methods and kits for identifying pregnant human beings at risk for placental bed disorder(s)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029903A1 (en) * 2009-09-10 2011-03-17 Flemming Velin Method for the preparation of micro-rna and its therapeutic application
EP2681336A4 (en) * 2011-03-02 2014-11-19 Groove Biopharma Corp ENHANCED BIODISTRIBUTION OF OLIGOMERS
EP2900822B1 (en) * 2012-09-26 2021-11-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligomers with improved off-target profile
ES2921623T3 (es) * 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente

Similar Documents

Publication Publication Date Title
JP2014237817A5 (enExample)
HK1254948A1 (zh) 源自间充质干细胞的外泌体及其应用
EP4374863A3 (en) Methods for generating stem cell-derived beta cells and uses thereof
JP2013005803A5 (enExample)
JP2014221779A5 (enExample)
WO2017070626A3 (en) Respiratory virus vaccines
WO2015170322A3 (en) Compositions and methods of using same for increasing resistance of infected mosquitoes
EP4269601A3 (en) Modified t cells and methods of making and using the same
WO2016073955A3 (en) Cells lacking b2m surface expression and methods for allogeneic administration of such cells
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
CL2012003723A1 (es) Compuestos derivados de acido 2-quinolinil-acetico; composicion farmaceutica; y uso en el tratamiento del vih y sida.
PL3174875T3 (pl) Sposób wytwarzania (4S)-4-(4-cyjano-2-metoksyfenylo)-5-etoksy-2,8-dimetylo-1,4-dihydro-1,6-naftyrydyno-3-karboksyamidu i jego oczyszczanie do zastosowania jako aktywny składnik farmaceutyczny
IL262944A (en) Viral particle for rna transfer, especially into cells involved in immune response
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
MX2014012164A (es) Composiciones a base de probioticos y un complejo de polen de abejas/arcilla, su preparacion y sus usos en nutricion y en terapeutica.
JP2016540026A5 (enExample)
JP2016540019A5 (enExample)
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
EP4549546A3 (en) Dendritic cell generator
ZA201806766B (en) Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
WO2016095934A3 (en) A novel genetic device to engineer cell behavior
EP4226937A3 (en) Non-neuroinvasive viruses and uses thereof
WO2015114633A8 (en) Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same
HUE037543T2 (hu) Di-homo-gamma linolénsavat (DGLA) tartalmazó liposzómák, az azokat tartalmazó készítmények és alkalmazásuk